Page Title
Clinical Trial Finder
Blaze a trail to better treatments and a cure for cystic fibrosis.
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 1-12 of 14 studies
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 1-12 of 14 studies
-
Anti-InflammatoryEnrolling
Study to evaluate BI 1291583 in adults with cystic fibrosis bronchiectasis. , protocol number Boehringer Ingelheim BI1397-0013BI 1291583 is a potential therapy intended to reduce inflammation in the lungs of people with bronchiectasis, the progressive lung disease that occurs in cystic fibrosis and other conditions. This study will test the safety, tolerability, and the effect on the body of BI 1291583.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
7
-
Length of Participation:
22 weeks
-
-
Anti-InflammatoryClosed to Enrollment
Study of INS1007/brensocatib tablets in adults with CF , protocol number Insmed INS1007-211This study will look at the safety, tolerability, and how the body processes INS1007/brensocatib tablets, a drug intended to reduce inflammation.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
8
-
Length of Participation:
56 days
-
-
Anti-InflammatoryClosed to Enrollment
Study to evaluate CB-280 in adults with cystic fibrosis and chronic Pseudomonas aeruginosa , protocol number Calithera CX-280-202This study will look at the safety and tolerability of CB-280, an oral drug taken twice a day intended to treat infections in the lung and reduce inflammation. Multiple doses of the drug will be tested in adults with cystic fibrosis and chronic Pseudomonas aeruginosa to find the best dose.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
6
-
Length of Participation:
2 months
-
-
Anti-InflammatoryClosed to Enrollment
Phase 2 study of JBT-101 in people with CF , protocol number Corbus JBT101-CF-002This study evaluated the safety and effectiveness of the anti-inflammatory drug JBT-101 (lenabasum), as well as how the body processes the drug, in adults with CF.
-
Age:
12 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40 to 100%
-
Number of Visits:
10
-
Length of Participation:
32 weeks
-
-
Anti-InflammatoryClosed to Enrollment
Phase 2 study of LAU-7b in adults with CF (APPLAUD) , protocol number Laurent LAU-14-01This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the anti-inflammatory drug LAU-7b and will use a placebo control.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40 to 100%
-
Number of Visits:
6
-
Length of Participation:
189 days
-
-
Anti-InflammatoryClosed to Enrollment
Phase 2 study of GS-5745 in adults with CF , protocol number Gilead GS-US-404-1808This study is taking place at multiple care centers across the U.S. It will look at the effectiveness of the anti-inflammatory drug GS-5745 and will use a placebo control.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40 to 80%
-
Number of Visits:
6
-
Length of Participation:
24 weeks
-
-
Anti-InflammatoryCompleted with Results
Multiple Dose Safety Study of SB-656933 in People with Cystic Fibrosis , protocol number GSK CF2110399The purpose of this study was to determine the safety, tolerability and pharmacodynamics of SB656933 in patients that have cystic fibrosis.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40 to 110%
-
Number of Visits:
7
-
Length of Participation:
8 weeks
-
-
Anti-InflammatoryCompleted with Results
KB001-A in people with CF and Pseudomonas aeruginosa , protocol number KaloBios KB001-05This study evaluated the safety and effectiveness of the drug KB001-A compared with placebo. This study was for people who have chronic Pseudomonas aeruginosa (Pa) airway infection.
-
Age:
12 Years to 50 Years
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40 to 100%
-
Number of Visits:
10
-
Length of Participation:
20 weeks
-
-
Anti-InflammatoryCompleted with Results
Phase 2 study of CTX-4430 in people with CF (EMPIRE) , protocol number Celtaxsys CTX-4430This study evaluated the safety and effectiveness of the anti-inflammatory drug CTX-4430 (acebilustat)This study evaluated the safety and effectiveness of the anti-inflammatory drug CTX-4430 (acebilustat).
-
Age:
18 Years to 30 Years
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
50% or greater
-
Number of Visits:
15
-
Length of Participation:
1 years
-
-
Anti-InflammatoryCompleted with Results
Phase 2 study of JBT-101 in people with CF , protocol number Corbus JBT101-CF-001This study evaluated the safety and effectiveness of the anti-inflammatory drug JBT-101 (lenabasum), as well as how the body processes the drug, in adults with CF.
-
Age:
18 Years to 65 Years
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
8
-
Length of Participation:
127 days
-
-
Anti-InflammatoryCompleted with Results
AquADEKs-2: Effects of an antioxidant-enriched multivitamin on inflammation and oxidative stress in people with CF , protocol number AquADEKs-IP-12This study evaluated the effects of an antioxidant-enriched multivitamin supplement on inflammation. This study was for people with CF who are pancreatic insufficient.
-
Age:
10 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40 to 100%
-
Number of Visits:
4
-
Length of Participation:
20 weeks
-
-
Anti-InflammatoryCompleted with Results
Phase 2 study of inhaled Alpha-1 HC in people with CF , protocol number Grifols T6005-201This study assessed the safety and tolerability of two different doses of once daily inhaled Alpha-1 anti-trypsin in people with CF.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
5
-
Length of Participation:
9 weeks
-
Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More